Target type: biologicalprocess
The process involved in the specification of cardiac cell identity. Once specification has taken place, a cell will be committed to differentiate down a specific pathway if left in its normal environment. [GOC:mtg_heart]
Cardiac cell fate specification is a complex and tightly regulated process that involves a series of molecular events, beginning with the commitment of pluripotent cells to the mesoderm lineage. This commitment is driven by transcription factors such as Brachyury and GATA4. Once mesodermal cells are specified, they enter the cardiogenic progenitor pool. Within this pool, cells undergo a series of signaling events, including Wnt, BMP, and FGF signaling, which determine their specific cardiac cell fate. These signaling pathways influence the expression of key transcription factors that govern cardiac cell fate, such as Nkx2.5, GATA4, and Tbx5. These factors act in a coordinated manner to activate genes required for the development of specific cardiac cell types.
Cardiac cell fate specification involves the formation of distinct cardiac cell types, including cardiomyocytes, endothelial cells, smooth muscle cells, and fibroblasts.
Cardiomyocytes, the contractile cells of the heart, are specified by the expression of cardiac-specific transcription factors, such as Myocardin, MEF2, and SRF. These factors regulate the expression of genes required for cardiomyocyte function, including sarcomeric proteins, ion channels, and calcium handling proteins.
Endothelial cells, which line the heart chambers and vessels, are specified by the expression of transcription factors such as ETS1, Fli1, and Tie2. These factors regulate the expression of genes required for endothelial cell function, including cell-cell adhesion molecules, vascular growth factors, and signaling receptors.
Smooth muscle cells, which contribute to the structure and function of the heart, are specified by the expression of transcription factors such as SM22, Myocardin, and SRF. These factors regulate the expression of genes required for smooth muscle cell function, including contractile proteins, cytoskeletal proteins, and signaling receptors.
Fibroblasts, which produce extracellular matrix components, are specified by the expression of transcription factors such as AP-1, Sp1, and TGF-β. These factors regulate the expression of genes required for fibroblast function, including collagen, elastin, and proteoglycans.
Cardiac cell fate specification is a highly dynamic process that requires precise temporal and spatial regulation of gene expression. Disruptions in this process can lead to congenital heart defects, highlighting the importance of understanding the molecular mechanisms that govern cardiac cell fate.'
"
Protein | Definition | Taxonomy |
---|---|---|
Integrin beta-1 | An integrin beta-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P05556] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
haloperidol | haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
1,3-ditolylguanidine | 1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the brain | toluenes | |
tirofiban | tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME. | L-tyrosine derivative; piperidines; sulfonamide | anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist |
arginyl-glycyl-aspartic acid | arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system | oligopeptide | |
arginyl-glycyl-aspartyl-serine | arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets | ||
glycyl-arginyl-glycyl-aspartyl-serine | glycyl-arginyl-glycyl-aspartyl-serine: synthetic peptide from fibronectins; inhibits experimental metastasis of murine melanoma cells | ||
d-arg-gly-asp-trp | arginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide | ||
l 738167 | L 738167: structure in first source | ||
cilengitide | Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells | oligopeptide | |
l 734217 | L 734217: fibrinogen receptor antagonist; structure given in first source | ||
cyclopamine | piperidines | glioma-associated oncogene inhibitor | |
arginyl-glycyl-aspartyl-phenylalanine | |||
cyclic(arg-gly-asp-d-phe-val) | |||
mk-0429 | |||
mocetinostat | mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11). mocetinostat: undergoing phase II clinical trials for treatment of cancer | aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline | antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent |
tr 14035 | N-(2,6-dichlorobenzoyl)-4-(2',6'-bismethoxyphenyl)phenylalanine: TR-14035 is the (L)-isomer; an antagonist of both alpha4beta1 and beta7 integrins; structure in first source | ||
bio 1211 | BIO 1211: integrin alpha4beta1 inhibitor; structure in first source |